The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable excitement within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication seems to provide notable improvements in fat loss compared to current therapies. Initial research trials have indicated significant decreases in weight , possibly sig